Key references: Management of people at risk of developing type 2 diabetes

  • Bell K, Shaw JE, Maple-Brown L, Ferris W, Gray S, Murfet G, et al. A position statement on screening and management of prediabetes in adults in primary care in Australia. Diabetes Res Clin Pract 2020;164:108188. https://www.ncbi.nlm.nih.gov/pubmed/32360708
  • Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359(9323):2072-7.http://www.ncbi.nlm.nih.gov/pubmed/12086760
  • Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374(9702):1677-86.http://www.ncbi.nlm.nih.gov/pubmed/19878986
  • Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2017;5(11):877-86.http://www.ncbi.nlm.nih.gov/pubmed/28917545
  • Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 2007;186(9):461-5.http://www.ncbi.nlm.nih.gov/pubmed/17484708